AKT inhibition mitigates GRP78 (glucose-regulated protein) expression and contribution to chemoresistance in endometrial cancers

International Journal of Cancer

Volumn 133, Issue 1, 2013, Pages 21-30

  Gray, Michael J ^a   Mhawech Fauceglia, Paulette ^b   Yoo, Eunjeong ^a   Yang, Wangrong ^a   Wu, Eijean ^b   Lee, Amy S ^a,b,c   Lin, Yvonne G ^a,b,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

AKT; chemoresistance; GRP78; MK2206

Indexed keywords

4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 (3 PIPERIDINYLMETHOXY) 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; CISPLATIN; GLUCOSE REGULATED PROTEIN 78; PROTEIN KINASE B; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; ENDOMETRIUM; ENDOMETRIUM CANCER; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TISSUE DISTRIBUTION; UPREGULATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEAT-SHOCK PROTEINS; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING;

EID: 84876694384     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27994     Document Type: Article

References (48)

1. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin 2012.
2. Wright JD, Barrena Medel NI, Sehouli J, et al. Contemporary management of endometrial cancer. Lancet 2012; 379: 1352-60.
3. Dedes KJ, Wetterskog D, Ashworth A, et al. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 2011; 8: 261-71.
4. Luo B, Lee AS,. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene 2012; [Epub ahead of print].
5. Pfaffenbach KT, Lee AS,. The critical role of GRP78 in physiologic and pathologic stress. Curr Opin Cell Biol 2011; 23: 150-6.
6. Sha H, He Y, Chen H, et al. The IRE1alpha-XBP1 pathway of the unfolded protein response is required for adipogenesis. Cell Metab 2009; 9: 556-64.
7. Xing X, Li Y, Liu H, et al. Glucose regulated protein 78 (GRP78) is overexpressed in colorectal carcinoma and regulates colorectal carcinoma cell growth and apoptosis. Acta Histochem 2011; 113: 777-82.
8. Uramoto H, Sugio K, Oyama T, et al. Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer 2005; 49: 55-62.
9. Fernandez PM, Tabbara SO, Jacobs LK, et al. Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res Treat 2000; 59: 15-26.
10. Pootrakul L, Datar RH, Shi SR, et al. Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin Cancer Res 2006; 12: 5987-93.
11. Delie F, Petignat P, Cohen M,. GRP78 Protein expression in ovarian cancer patients and perspectives for a drug-targeting approach. J Oncol 2012; 2012: 468615.
12. Huang LW, Lin CY, Lee CC, et al. Overexpression of GRP78 is associated with malignant transformation in epithelial ovarian tumors. Appl Immunohistochem Mol Morphol 2012; 20: 381-5.
13. Lee E, Nichols P, Spicer D, et al. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res 2006; 66: 7849-53.
14. Chen TC,. GRP78/BiP modulation of GRP78/BiP in altering sensitivity to chemotherapy. Methods Enzymol 2011; 491: 25-36.
15. Fu Y, Li J, Lee AS,. GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis. Cancer Res 2007; 67: 3734-40.
16. Mann MJ, Hendershot LM,. UPR activation alters chemosensitivity of tumor cells. Cancer Biol Ther 2006; 5: 736-40.
17. Reddy RK, Mao C, Baumeister P, et al. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem 2003; 278: 20915-24.
18. Lin Y, Wang Z, Liu L, et al. Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells. Lung Cancer 2011; 71: 291-7.
19. Kelber JA, Panopoulos AD, Shani G, et al. Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways. Oncogene 2009; 28: 2324-36.
20. Ni M, Zhang Y, Lee AS,. Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting. Biochem J 2011; 434: 181-8.
21. Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, et al. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 2005; 117: 755-63.
22. Peng DJ, Wang J, Zhou JY, et al. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun 2010; 394: 600-5.
23. Hayakawa J, Ohmichi M, Kurachi H, et al. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 2000; 60: 5988-94.
24. Hoekstra AV, Ward EC, Hardt JL, et al. Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1. Gynecol Oncol 2008; 108: 609-18.
25. Fraser M, Bai T, Tsang BK,. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 2008; 122: 534-46.
26. Gagnon V, Mathieu I, Sexton E, et al. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 2004; 94: 785-95.
27. Abedini MR, Muller EJ, Bergeron R, et al. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene 2010; 29: 11-25.
28. Kanamori Y, Kigawa J, Itamochi H, et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res 2001; 7: 892-5.
29. St-Germain ME, Gagnon V, Mathieu I, et al. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells. Int J Oncol 2004; 24: 1311-24.
30. Gagnon V, St-Germain ME, Parent S, et al. Akt activity in endometrial cancer cells: regulation of cell survival through cIAP-1. Int J Oncol 2003; 23: 803-10.
31. Wey S, Luo B, Tseng CC, et al. Inducible knockout of GRP78/BiP in the hematopoietic system suppresses Pten-null leukemogenesis and AKT oncogenic signaling. Blood 2012; 119: 817-25.
32. Fu Y, Wey S, Wang M, et al. Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium. Proc Natl Acad Sci USA 2008; 105: 19444-9.
33. Misra UK, Pizzo SV,. Ligation of cell surface GRP78 with antibody directed against the COOH-terminal domain of GRP78 suppresses Ras/MAPK and PI 3-kinase/AKT signaling while promoting caspase activation in human prostate cancer cells. Cancer Biol Ther 2010; 9: 142-52.
34. Moxley KM, McMeekin DS,. Endometrial carcinoma: a review of chemotherapy, drug resistance, and the search for new agents. Oncologist 2010; 15: 1026-33.
35. Pyrko P, Schonthal AH, Hofman FM, et al. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 2007; 67: 9809-16.
36. Martin S, Hill DS, Paton JC, et al. Targeting GRP78 to enhance melanoma cell death. Pigment Cell Melanoma Res 2010; 23: 675-82.
37. Mandic A, Hansson J, Linder S, et al. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003; 278: 9100-6.
38. Jiang L, Zhang L, Wang Q, et al. [Down-regulation of GRP78 Enhances Chemotherapy Sensitivity to VP-16 in Lung Adenocarcinoma.]. Zhongguo Fei Ai Za Zhi 2009; 12: 1159-63.
39. Gonzalez-Gronow M, Selim MA, Papalas J, et al. GRP78: a multifunctional receptor on the cell surface. Antioxid Redox Signal 2009; 11: 2299-306.
40. Sato M, Yao VJ, Arap W, et al. GRP78 signaling hub a receptor for targeted tumor therapy. Adv Genet 2010; 69: 97-114.
41. Misra UK, Payne S, Pizzo SV,. Ligation of prostate cancer cell surface GRP78 activates a proproliferative and antiapoptotic feedback loop: a role for secreted prostate-specific antigen. J Biol Chem 2011; 286: 1248-59.
42. Misra UK, Mowery Y, Kaczowka S, et al. Ligation of cancer cell surface GRP78 with antibodies directed against its COOH-terminal domain up-regulates p53 activity and promotes apoptosis. Mol Cancer Ther 2009; 8: 1350-62.
43. Gonzalez-Gronow M, Cuchacovich M, Llanos C, et al. Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. Cancer Res 2006; 66: 11424-31.
44. Dong D, Stapleton C, Luo B, et al. A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis. Cancer Res 2011; 71: 2848-57.
45. Dai RY, Chen SK, Yan DM, et al. PI3K/Akt promotes GRP78 accumulation and inhibits endoplasmic reticulum stress-induced apoptosis in HEK293 cells. Folia Biol (Praha) 2010; 56: 37-46.
46. Pfaffenbach KT, Pong M, Morgan TE, et al. GRP78/BiP is a novel downstream target of IGF-1 receptor mediated signaling. J Cell Physiol 2012; 227: 3803-11.
47. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-7.
48. Chappell WH, Steelman LS, Long JM, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011; 2: 135-64.